Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure

被引：16

作者：

Duncker D. ^{[1
]}

Veltmann C. ^{[1
]}

机构：

[1] Rhythmology and Electrophysiology, Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover

来源：

Current Heart Failure Reports | 2018年 / 15卷 / 6期

关键词：

Heart failure; Newly diagnosed cardiomyopathy; Sudden cardiac death; Wearable defibrillator;

D O I：

10.1007/s11897-018-0415-7

中图分类号：

学科分类号：

摘要：

Purpose of Review: The wearable defibrillator (WCD) was shown to be safe and effective in detecting and terminating ventricular tachyarrhythmias and therefore allows temporary protection from sudden cardiac death. This review gives an overview of the current data on WCD in newly diagnosed cardiomyopathy. Recent Findings: Patients with newly diagnosed heart failure and reduced LVEF appear to have an increased risk of ventricular tachyarrhythmias, which may decrease over time when heart failure medication is optimized and left ventricular function improves. This was shown to apply for patients with ischemic and non-ischemic cardiomyopathy, including peripartum cardiomyopathy. Prolongation of the WCD period may support to further optimization of heart failure medication, by protecting the patient from sudden cardiac death during this time and to avoid untimely ICD implantation. Summary: The WCD should be considered in structured patient management for newly diagnosed heart failure during the early phase of the disease. Careful patient selection, structured patient management, and patient’s compliance is crucial for a successful WCD strategy. © 2018, The Author(s).

引用

页码：368 / 375

页数：7

共 66 条

[1]

Al-Khatib S.M., Stevenson W.G., Ackerman M.J., Bryant W.J., Callans D.J., Curtis A.B., Et al., AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, J am Coll Cardiol, (2017)

[2]

Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, 2016, pp. 128-185, (2016)

[3]

Priori S.G., Blomstrom-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., Elliott P.M., Fitzsimons D., Hatala R., Hindricks G., Kirchhof P., Kjeldsen K., Kuck K.H., Hernandez-Madrid A., Nikolaou N., Norekval T.M., Spaulding C., van Veldhuisen D., 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of

[4]

Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., Connolly S.J., Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction, N Engl J Med, 351, pp. 2481-2488, (2004)

[5]

Steinbeck G., Andresen D., Seidl K., Brachmann J., Hoffmann E., Wojciechowski D., Kornacewicz-Jach Z., Sredniawa B., Lupkovics G., Hofgartner F., Lubinski A., Rosenqvist M., Habets A., Wegscheider K., Senges J., Defibrillator implantation early after myocardial infarction, N Engl J Med, 361, pp. 1427-1436, (2009)

[6]

Sheppard R., Mather P.J., Alexis J.D., Starling R.C., Boehmer J.P., Thohan V., Pauly D.F., Markham D.W., Zucker M., Kip K.E., McNamara D., Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2, J Card Fail, 18, pp. 675-681, (2012)

[7]

Goldenberg I., Moss A.J., McNitt S., Zareba W., Hall W.J., Andrews M.L., Wilber D.J., Klein H.U., Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II, J Am Coll Cardiol, 47, pp. 1811-1817, (2006)

[8]

Wilber D.J., Zareba W., Hall W.J., Brown M.W., Lin A.C., Andrews M.L., Burke M., Moss A.J., Time dependence of mortality risk and defibrillator benefit after myocardial infarction, Circulation, 109, pp. 1082-1084, (2004)

[9]

Al-Khatib S.M., Hellkamp A., Curtis J., Mark D., Peterson E., Sanders G.D., Et al., Non-evidence-based ICD implantations in the United States, JAMA American Medical Association, 305, pp. 43-49, (2011)

[10]

Solomon S.D., Zelenkofske S., McMurray J.J.V., Finn P.V., Velazquez E., Ertl G., Harsanyi A., Rouleau J.L., Maggioni A., Kober L., White H., van de Werf F., Pieper K., Califf R.M., Pfeffer M.A., Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both, N Engl J Med, 352, pp. 2581-2588, (2005)

← 1 2 3 4 5 6 7 →